PA
CYTK icon

Perceptive Advisors’s Cytokinetics CYTK Stock Holding History

Perceptive Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,317
Closed -$2.53M – 116
2023
Q4 		$2.53M Buy
+30,317
New +$1.1M 0.06% 86
2015
Q2 		– Sell
-30,227
Closed -$205K – 178
2015
Q1 		$205K Buy
+30,227
New +$226K 0.02% 141

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors's CYTK Position: Q1 2024 in Review

Perceptive Advisors sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 30,317 shares — an estimated $2.53M sold.

Perceptive Advisors first reported a position in CYTK in Q1 2015 and held it in 2 quarters. The position peaked at $2.53M in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Perceptive Advisors reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
  • Perceptive Advisors sold 30,317 Cytokinetics shares in Q1 2024, an estimated $2.53M.
  • Perceptive Advisors first reported a position in Cytokinetics in Q1 2015 and held it in 2 quarters.
  • Perceptive Advisors's Cytokinetics position peaked at $2.53M in Q4 2023.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.